Form 4 Filing for Apogee Therapeutics, Inc.

Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc., reported the sale of 811 shares of Common Stock on May 1, 2026, for an average price of $81.02 per share. This transaction was part of a Rule 10b5-1 trading plan. Following this sale, Henderson directly owns 174,560 shares. Additionally, Henderson sold 900 shares of Common Stock for an average price of $82.60 per share, resulting in 173,660 shares owned post-transaction. Another transaction involved the sale of 289 shares of Common Stock at an average price of $83.16 per share, leaving 173,371 shares owned. All sales were executed under a pre-arranged trading plan.